IO Frontiers World 2019


Claudia Zylberberg

Dr Claudia Zylberberg

CEO, Akron Biotech

Claudia Zylberberg, PhD, serves as Founder and Chief Executive Officer of Akron Biotech ( Akron Biotech, a leading CMDO in the field of regenerative medicine, innovates, develops and manufactures a range of products and technologies for cell and gene therapy and tissue engineering. Akron focuses on cGMP-compliant recombinant and human proteins, media and supplements, cryopreservation media and 3D scaffolds for active delivery, tissue reconstruction and cell culture.

Dr. Zylberberg has over 30 years of experience in the international biopharmaceutical industry. Her expertise is focused on the areas of recombinant protein production and human-derived blood products. She also has co-founded and successfully exited a clinical CRO and a family stem cell bank. She holds numerous patents and peer-reviewed publication records. She has developed products to support industry growth, like cryomedias and others. Dr. Zylberberg has several patent-pending technologies and grants through NIH, the Department of Defense and other industry consortia. She has authored and co-authored many scientific articles and developed several commercial products for use in the field of cellular biology. She has also authored a children’s book on genetics called “You’re full of genes.”

Due to her vast understanding of the global stem cell market, Dr. Zylberberg has advised and consulted organizations worldwide on the commercialization of cell banking and therapies. She participates as an Advisor for the US Pharmacopeia, ISO US TAG standards, and other international bodies in relation to standard-setting initiatives for biologics and ancillary materials critical for the production of cellular therapies, bioprocessing, and logistics. Recently, Dr. Zylberberg co-founded the Standard Coordinating Body, an organization that coordinates and addresses many of the standards for this new industry. Among other organizations, Dr. Zylberberg is a member of the National Academy of Science (Regenerative Medicine Forum), BioFlorida Board of Directors, the Business Development Board of Palm Beach County, Alliance of Regenerative Medicine (ARM), the International Society of Cell Therapies (ISCT), Cord Blood Association, and Biomedical Engineering University of Miami.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy